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Sirs,
Frontotemporal dementia (FTD) is the second most-
common neurodegenerative dementia after Alzheimer’s
disease (AD), with a frequency of 12%–20% among
patients with an onset of dementia below 65 years. Causal
mutations leading to FTD were identified in the micro-
tubule-associated protein tau (MAPT) gene located at
17q21. In several autosomal dominant tau-negative FTD
families, however, mutations in MAPT could not be
identified, despite conclusive linkage to 17q21 [1, 2, 3].
We hypothesized that this subtype of FTD could result
from mutations in the gene encoding presenilin (PS)
homologue 2 (PSH2), located 50 kb upstream of MAPT.
PSH2 is one of five members of a novel family of proteins
showing membrane topology and putative catalytic
domains similar to PS [4]. Because mutations in prese-
nilins 1 and 2 are responsible for early onset AD [5]
(http://molgen-www.uia.ac.be/ADMutations), mutations
in PSHs might also lead to neurodegeneration. Previously,
mutation analysis of PSH2 in probands of four tau-
negative FTD families failed to identify PSH2 mutations
[4], but these families were not informative for linkage to
17q21.
We described a four-generation family, 1083, ascer-
tained in a population-based study in the Netherlands [6],
which presented with a clinical phenotype similar to FTD
and a mean onset age of 64.9 years (range 53–79 years)
[2]. Autopsy demonstrated severe frontal atrophy and
complete lack of tau neuropathology in the presence of
ubiquitin-positive tau-negative inclusions. A genome-
wide scan identified conclusive linkage (multipoint
LOD score=5.51) in a candidate region of 4.8 cM at
17q21 comprising MAPT. Extensive mutation analysis of
MAPT coding and regulatory sequences failed to identify
disease-related mutations [2].
In this study, we performed mutation analysis of PSH2
by direct sequencing of three overlapping PCR amplicons
of genomic DNA between positions g.6 and g.2195 in
XM_091623.4, corresponding to the only coding exon of
PSH2, and including 67 bp upstream and 68 bp down-
stream regulatory sequences. In total we identified 5
novel (Table 1) and 10 known single nucleotide poly-
morphisms (SNPs) (see electronic supplementary Fig. 1).
Segregation analysis in the family indicated that only 1
novel SNP g.1698G>A was contained in the disease
haplotype leading to a silent mutation at codon S542. We
used a pyrosequencing assay to analyze 89 Dutch control
individuals and identified 2 controls that were homozy-
gous and 20 heterozygous for the A allele, resulting in a
minor allele frequency of 13.5%. Segregation analysis
also illustrated that 4 of the 5 novel SNPs were in linkage
disequilibrium with the extended MAPT haplotypes H1/
H2, defined by polymorphic alleles in MAPT exons 1, 2,
3, 9, 11, and 13 [7] (see electronic supplementary Fig. 1).
R. Rademakers · M. Van den Broeck · C. van Duijn · C. Van
Broeckhoven · M. Cruts
Department of Molecular Genetics,
Flanders Interuniversity Institute for Biotechnology,
University of Antwerp, Antwerpen, Belgium
K. Sleegers · C. van Duijn
Genetic Epidemiology Group,
Department of Epidemiology and Biostatistics,
Erasmus Medical Center, Rotterdam, The Netherlands
M. Cruts ())
Department of Molecular Genetics (VIB8), Neurogenetics Group,
University of Antwerp (Campus UIA),
Universiteitsplein 1, 2610 Antwerpen, Belgium
e-mail: marc.cruts@ua.ac.be
Tel.: +32-3-8202631
Fax: +32-3-8202541
These data confirmed thatMAPT haplotype blocks extend
to PSH2, as previously shown by Ponting et al. [4].
In conclusion, we excluded by direct sequencing
pathogenic mutations in PSH2 as a causative defect for
17q21-linked tau-negative FTD using mutation and
segregation analysis in the most-informative family
known to date. It is also unlikely that the single PSH2
coding exon or part of it is deleted, since all patients were
heterozygous for the linked SNP g.1698G>A, and since in
all three PCR amplicons heterozygote SNPs were iden-
tified in at least one patient. A gene duplication of PSH2
cannot be fully excluded by the methods we used in the
mutation analysis. However, the apparent accumulation of
non-synonymous SNPs within the PSH2 coding sequence
is indicative of a non-functional processed pseudogene [4]
(this study). Therefore, our data suggest that another
defective gene at 17q21 should also be considered for this
subtype of FTD. Since 64% of all FTD patients do not
display tau pathology, and since the MAPT mutation
frequency in familial FTD is less than 50%, the genetic
defect leading to tau-negative dementia might be an
important factor in the etiology of FTD. Its identification
will likely contribute to our understanding of this
important neurodegenerative dementia.
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Table 1 Novel single nucleotide polymorphisms (SNPs) in the
gene for presenilin homologue 2 (PSH2). For all SNPs nucleotide
numbering is described relative to XM_091623.4
Genomic
position
Amino acid
change
Minor allele
frequencya
g.1698G>A S542 13.5%
g.2000C>G P643R 38%
g.2019T>C H649 38%
g.2031G>A Q653 38%
g.2137C>A  38%
a For g.1698G>A, allele frequencies were calculated in 190
unrelated control chromosomes, the others were calculated in the
3 patients and 1 control of family 1083 of whom 3 shared the same
haplotype
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